PYXS News and Press, Pyxis Oncology Inc. From 11/03/25

2025-11-03 07:46:49 ET More on Pyxis Oncology Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade) Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earnings data for Pyxis Oncology Financial information for Pyxis Onco...

-  Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the fourth quarter of 2025 -  Clinical update to focus on preliminary data from Ph...

Translational data validate mechanism of first-in-concept extracellular-cleaving ADC micvotabart pelidotin (MICVO) MICVO combats solid tumors through three-pronged mechanism of action: direct tumor cell killing, bystander effect, and immunogenic cell death Findings demonstrate MIC...

BOSTON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers, today announced the appointment of Alex Kane, MBA, as Senior Vice President, Investor Relations & Capit...

2025-09-12 11:44:56 ET ... Read the full article on Seeking Alpha For further details see: Pyxis Oncology: Readouts Ahead, Although Cash Might Dwindle (Rating Downgrade)

2025-08-14 17:34:15 ET More on Pyxis Oncology Seeking Alpha’s Quant Rating on Pyxis Oncology Historical earnings data for Pyxis Oncology Financial information for Pyxis Oncology Read the full article on Seeking Alpha For further details see: ...

–  Phase 1 monotherapy expansion study of micvotabart pelidotin (MICVO) for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients progressing well with preliminary data in second half of 2025 and first half of 2026 –  Phase 1/2 combi...

Western Uranium & Vanadium Corp (WSTRF) is expected to report for Q2 2025 IceCure Medical Ltd. (ICCM) is expected to report $-0.06 for Q2 2025 TFF Pharmaceuticals Inc - Ordinary Shares (TFFP) is expected to report for quarter end 2025-06-30 Scientific Industries, Inc. (SCND) is ex...

Pyxis Oncology Inc. (PYXS) is expected to report $-0.36 for Q2 2025

BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the B...